Alfaxan Multidose is a drug owned by ZOETIS INC. It is protected by 10 US drug patents filed from 2021 to 2032. Out of these, 8 patents are active and 2 patents have expired. Details of Alfaxan Multidose’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US12582662 | 27 Nov, 2032 | Active |
| US12582662 | 27 Nov, 2032 | Active |
| US9492552 | 27 Nov, 2032 | Active |
| US9492552 | 27 Nov, 2032 | Active |
| US10188664 | 27 Nov, 2032 | Active |
| US12303519 | 27 Nov, 2032 | Active |
| US7897586 | 21 Mar, 2021 | Expired |
| US7897586 | 21 Mar, 2021 | Expired |
Exclusivity Information
Alfaxan Multidose holds 2 exclusivitys out of which 2 have expired. Details of Alfaxan Multidose's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | Sep 06, 2017 |
| NCI | Jun 06, 2021 |
About Alfaxan Multidose
Alfaxan Multidose is a drug
owned by ZOETIS INC.
Alfaxan Multidose uses
Alfaxalone as the active
ingredient.
Active Ingredient:
Alfaxan Multidose uses
Alfaxalone as the active ingredient.
Check out other Drugs and Companies using
Alfaxalone ingredient.